Suppliers of counterfeit medicines and medical devices are exploiting public fears around coronavirus (COVID-19), warns the Medicines and Healthcare products Regulatory Agency (MHRA), the UK's medicines and medical devices regulator.
In an effort to tackle the economic disruption caused by Coronavirus (COVID-19), the government recently announced that it would introduce and subsidise a Job Retention Scheme.
On Saturday 28 March, the Secretary of State for Business Energy and Industrial Strategy announced changes to the insolvency regime with the aim of keeping viable companies trading through the unprecedented challenge of the COVID-19 pandemic.
New legislation came into force at 1pm on 26 March 2020, to impose restrictions in order to reduce the risk to public health arising from the Coronavirus.
The Job Retention Scheme will enable employers to retain staff who are not required to work for the foreseeable future, who may otherwise be made redundant.
With a significant proportion of the population working from home for the foreseeable future, organisations are having to adapt to new ways of accessing systems and communicating.
In any difficult financial climate, tenants may look for ways to reduce their financial burden by moving to smaller premises or closing up shop completely.
The Coronavirus (COVID-19) pandemic continues to heavily impact the economy, particularly following the announcement of a 'lockdown' on Monday evening.
